Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.

Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D.

N Engl J Med. 1990 May 3;322(18):1260-4.

2.

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie G, McLaughlin D.

N Engl J Med. 1982 Jan 28;306(4):189-94.

PMID:
7033782
3.

Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.

Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P.

N Engl J Med. 1979 Oct 18;301(16):855-8.

PMID:
384248
4.

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.

Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al.

N Engl J Med. 1993 Nov 4;329(19):1370-6.

5.

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW.

N Engl J Med. 1992 Nov 19;327(21):1485-9.

6.

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al.

N Engl J Med. 1992 Apr 9;326(15):975-82.

7.
8.

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, et al.

N Engl J Med. 1986 Oct 30;315(18):1109-14.

PMID:
3531862
9.

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.

Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, Jay RM, Neemeh J.

Ann Intern Med. 1991 Apr 1;114(7):545-51.

PMID:
1848054
10.

Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.

Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG.

Thromb Haemost. 1994 Aug;72(2):191-7.

PMID:
7831650
11.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

N Engl J Med. 1997 Feb 6;336(6):393-8.

12.
13.
14.

Anticoagulant therapy in deep venous thrombosis. A randomized controlled study.

Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen HH, Nielsen BO, Petersen JB, Bechgaard P.

Thromb Res. 1994 Feb 15;73(3-4):215-26.

PMID:
8191414
15.

Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.

Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, et al.

Thromb Haemost. 1995 Aug;74(2):606-11.

PMID:
8584992
16.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

17.

A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M.

N Engl J Med. 1986 Oct 9;315(15):925-9.

PMID:
3531851
18.

The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.

Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA.

Arch Intern Med. 1997 Nov 10;157(20):2317-21.

PMID:
9361572
20.

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH.

N Engl J Med. 1996 Mar 14;334(11):682-7. Erratum in: N Engl J Med 1997 Oct 23;337(17):1251.

Items per page

Supplemental Content

Write to the Help Desk